1-800-710-4674

Find a Doctor

Return to Physician Search

Physician Profile

 
Portrait photo of Dr Basel Yanes OHC medical oncologist

Basel Yanes, M.D.

“I like being able to help my patients receive cutting edge chemotherapy. And I also enjoy the evolution of the science of hematology and oncology.”
Learn More.

Practices

Hematology
Medical Oncology

Locations

Dayton

Request
appointment

or call
1-800-710-4674

SPECIALTIES

Hematology
Oncology

MEDICAL INTERESTS

Hematology
Breast cancer

PERSONAL INTERESTS

In his free time, Dr. Yanes enjoys reading, the arts, and sports. He loves reading about history and current events, visual and performing arts, and he is a collector of glass art. Dr. Yanes is a fan of Real Madrid Soccer and Ohio State football.

MEDICAL SCHOOL

University of Damascus, Syria

RESIDENCY

Miami Valley Hospital, Dayton, Ohio

FELLOWSHIP

The Ohio State University, Columbus, Ohio

CERTIFICATIONS & LICENSURES

American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Hematology
License – State Medical Board of Ohio
License – State of Illinois

ACADEMIC POSITIONS

Clinical Professor of Medicine, Wright State University, Dayton, Ohio

PROFESSIONAL ASSOCIATIONS

American Medical Association
American Society of Hematology
American Society of Clinical Oncology
American College of Physicians
International Association for the Study of Lung Cancer
International Society for the Study of Comparative Oncology
International Society of Hematology
National Surgical Adjuvant Breast Project
Ohio State Medical Association
Southwest Oncology Group
Montgomery County Medical Society
Dayton Clinical Oncology Program

PRESENTATIONS

G. King, B. Yanes, P. Hurtobuise, S. Balcerzak, A. Lobuglio: Lymphocytes and Monocytes Function in Successfully Treated Lymphoma Patients. Presented at the Central Society of Clinical Research meeting. (Chicago, Illinois – November, 1975)

B. Yanes, P. Hurtobuise, S. Balcerzak, A. Lobuglio, G. King: Impaired Response to Neoantigens in Successfully Treated Lymphoma Patients. Presented at the American Society of Hematology meeting. (Dallas, Texas – 1975)

J. Bullock, B. Yanes: Carcinoembryonic Antigen in Opthalmology. Presented at the Association For Research in Vision and Opthalmology meeting. (Sarasota, Florida – May, 1978)

B. Yanes, J. Quinones: In 111 Chloride Bone Marrow Scan, A Valuable Technique in

B. Yanes: Bronchial Adenocarcinoma, Primary vs. Metastatic. Presented at the Thirteenth International Congress of Chemotherapy. (Vienna, Austria – September, 1983)

B. Yanes: Carcinoembryonic Antigen in Metastatic Breast Carcinoma. Presented at the First Immunology Symposium. (Cleveland Clinic, - May, 1983)

B. Yanes: Prognostic Factors in Metastatic Breast Carcinoma. Presented at the Sixth Annual Breast Cancer Symposium. (San Antonio, Texas – November, 1983)

B. Yanes, A. Batata: Multiple Myeloma. Presented on the Ohio Medical Education Network. (January, 1984)

B. Yanes, S. Ross, A. Batata: Abnormal Lymphocytes, Subsets, and Function Following Adjuvant Chemotherapy of Breast Carcinoma. Presented at the Twentieth International Congress of Hematology. (Buenos Aires, Argentina – September, 1984)

Yanes, S. Ross, A. Batata: Abnormal Immune Function Following Adjuvant Chemotherapy of Breast Carcinoma. Presented at the Seventh Annual Breast Cancer Symposium.  (San Antonio, Texas – December 1984)

Yanes: Effective Treatment of Tamoxifen Induced Hot Flashes.  Presented at the Ninth Annual Breast Cancer Symposium.  (San Antonio, Texas – December, 1984)

Yanes: Rare Human Example of Growth Kinetics in Breast Carcinoma.  Presented at the Ninth Annual Breast Cancer Symposium.  (San Antonio, Texas – October, 1986)

Batata, B. Shen, B.Yanes, et al. (Presented by B. Yanes):  Quantitation of surface immunoglobulin (SIG) intensity on the lymphocytes of B. chronic lympoid leukemia (B. CLL) is valuable in the differential diagnosis between the common sub-types.  Presented at the Thirty-fourth Annual Meeting of the American Society of Hematology.  (Anaheim, California – December 4-8, 1992)

PUBLICATIONS

King, B. Yanes, P. Hurtobuise, S. Balcerzak, A. Lobuglio: Lymphocytes and Monocytes Function in Successfully Treating Lymphoma Patients.  Clinical Research V-23, p. 523. (1975)

Yanes, P. Hurtobuise, S. Balcerzak, A. Lobuglio, G. King: Impaired Response to Neoantigens in Successfully Treated Lymphoma Patients.  Blood V-46, No. 5, p. 1015. (1975)

King, B. Yanes, P. Hurtobuise, S. Balcerzak, A. Lobuglio: Immune Function in Successfully Treated Lymphoma Patients.  Journal of Clinical Investigation 57, pp 1451 –1460.  (1976)

Bullock, B. Yanes, M. Kelly, L. McDonald: Non-Hodkin’s Lymphoma Involving the Optic Nerve. Annuals of Ophthalmology 11, pp 1477-1480.  (1979)

Bullock, B. Yanes: Metastatic Tumor of the Orbit. Annals of Ophthalmology 12, pp 1392-1394.  (1980)

Yanes, N. Martin, J. Ungerleider: Chemotherapy Induced Ovarian Failure. Clinical Research V-28, No. 1, 56A  (February, 1980)

Bullock, B. Yanes: Ophthalmic Manifestations of Metastatic Breast Cancer.  Ophthalmology 87, pp 971-973.  (1980)

Yanes, J.Quinones: In 111 Chloride Bone Marrow Scan, A Valuable Techniques in Evaluating Aphasia. Proceedings the Sixth Meeting, European and African Division of the International Society of Hematology,  A-11-6, p 167. (1981)

Kohsaki, B. Yanes, J.S. Ungerleider, M.J. Murphy: Non-Frozen Preservation of Committed Hematopoietic Stem Cells from Normal Human Bone Marrow.  Stem Cells  1, pp 111-123. (1981)

Yanes: Endobronchial Metastases. Proceeding of the Nineteenth Meeting of the American Society of Clinical Oncology V-2, C-729,  p. 187. (May, 1983)

Yanes: Prognostic Factors in Metastatic Breast Carcinoma.  Breast Cancer Research and and Treatment V-3, p. 318  (1983)

Yanes: Bronchial Adenocarcinoma,  Primary vs. Metastatic. Proceedings of the Thirteenth International Congress of Chemotherapy  Part 281, pp 128-130.  (September, 1983)

Yanes, S. Ross, A. Batata: Abnormal Lymphocytes, Subsets, and Function Following Adjuvant Chemotherapy of Breast Carcinoma.  Proceedings of the Twentieth International Congress of Hematology A-549.  (September, 1984)

Yanes, S. Ross, A. Batata: Impaired Immune Function Following Adjuvant Chemotherapy of Breast Carcinoma.  Breast Cancer Research and Treatment  V-4, p. 338.  (1984)

Cantini, B. Yanes: Acute Myelogenous Leukemia in Pregnancy.  Southern Medical Journal 77, pp 1050-1052.  (1984)

Bullock, G.B. Bartley, R. Jean Campbell, B. Yanes, P. Connelly, J. Funkhouser: Necrobiotic Xanthogranuloma with Paraproteinemia – Case Report and a Pathogenic Theory.  Ophthalmology 93, pp 1233-1236.  (1986)

Yanes: Effective Treatment of Tamoxifen Induced Hot Flashes.  Breast Cancer Research and Treatment V-8, p. 89 (1986)

Yanes: Rare Human Growth Kinetics in Breast Carcinoma.  Breast Cancer Research and Treatment V-8, p. 103. (1986)

Batata, B. Shen, B. Yanes, et al.: The Complementary Roles of Surface Immunoglobulin Clonality and Fluorescence Intensity,  Mouse Rosettes and CD-5 in the Diagnosis of B. Chronic Lymphocytic Leukemia. International Journal of Oncology 2, pp 425-430.  (1993)

Batata, B. Shen, B. Yanes, et al.: Quantitation of Surface Immunoglobulin (SIG) Intensity on the Lymphocytes of B. Chronic Lymphoid Leukemias (B.CLL) is Valuable in the Differential Diagnosis Between the Common Sub-types.  Blood V-80, N10, Supplemental p. 38. (1992)

Yanes: Self-Referral by Physicians (letter). New England Journal of Medicine V-328, p 1278. (1993)

Troesch, C. Rodehaver, E. Delaney, B. and B. Yanes: The Influence of Guided Imagery In Chemotherapy – Related Nausea and Vomiting.  Oncology Nursing Forum V-20, p. 1179.  (1993)

Yanes, T. Karaman: Surveillance of Breast Cancer Patients Following Adjuvant Chemotherapy.  Proceedings of the American Society of Clinical Oncology V-16, p. 119. (1995)

As a member of the OHC team, Dr. Yanes has full access to the available clinical trials current offered at OHC. We encourage our patients to discuss all of their healthcare options — including Clinical Trials — with their doctor.

Dr. Yanes’ Pharmaceutical Research:
Principal Investigator:
U.S. Bioscience; WR 27-29 with Cisplatin in Lung Cancer

Principal Investigator:
Pharmaceutical Research, Erythropoietin in CLL

Principal Investigator:
Parexel; Tirapazamine versus Tirapazamine and Cisplatin in Non-Small Cell Lung Cancer

Principal Investigator:
Novartis 026; Letrozole versus Letrozole and Tamoxifen in Metastatic Breast Cancer

Principal Investigator:
Bristol; Taxol in Advanced Head and Neck Cancer

Principal Investigator:
Schering-Plough; Intron A versus PEG Intron in CML

Principal Investigator:
Immunex; Novantrone in Prostate Cancer

Principal Investigator:
Biocrystal; Rituxan in Metastatic Colorectal Cancer

Principal Investigator:
Coulter; Iodine-131 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkins Lymphoma

Principal Investigator:
Genetech; Recombinant Tissue Plasminogen Activator (rt-PA) for Restoration of Function to Central Venous Access Devices

Principal Investigator:
Chiron; Interleukin 2 in an Alternative Dose for Metastatic Renal Cell Carcinoma

Principal Investigator:
Isis; A prospective, randomized, open-label Phase III Trial of Chemotherapy in combination with Isis in patients with advanced Non-Small Cell Lung Carcinoma.

Principal Investigator:
Janssen; A Phase III trial of gemcitabine plus placebo versus gemcitabine plus R11577 in subjects with advanced Pancreatic Cancer.

Principal Investigator:
Novartis 025; Letrozole versus Tamoxifen in Metastatic Breast Cancer.

Principle Investigator:
Amgen; An open-label, randomized study to develop a screening tool for functional capacity in anemic subjects with Non-myeloid Malignancies receiving chemotherapy and Darbepoetin alfa (NCSP).

Principle Investigator:
Genentech; Rituxan in combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) chemotherapy as initial therapy for patients with aggressive Non-Hodgkins Lymphoma.

Principal Investigator:
Amgen;  A randomized, open-label, study of primary prophylaxis with Neulasta™, versus secondary prophylaxis as an adjunct to chemotherapy in elderly patients with cancer.

Principal Investigator:
Quality of Life Study using Navelbine with Gemzar versus Paraplatin in combination with Taxol in chemotherapy-naive subjects, with inoperable Stage IIIB or IV Non-Small Cell Lung Cancer.

Principal Investigator:
Amgen, 20020132, A study to assess symptom burden in subjects with NonMyeloid Malignancies receiving chemotherapy and Aranesp™.

Principal Investigator:
Ortho-Biotech, #PR02-27-015, “An open-labeled pilot study to evaluate the effects of High Dose Procrit® (Epoetin Alfa) in maintaing hemoglobin levels in anemic cancer patients receiving chemotherapy on a weekly or every 4 week regimen”.

Principal Investigator:
Ortho-Biotech, #PR02-27-016, “An open-labeled pilot study to evaluate the effects of High Dose Procrit® (Epoetin Alfa) in maintaining hemoglobin levels in anemic cancer patients receiving chemotherapy on an every 3 week regimen”.

Principal Investigator
Corixa, Protocol #CCBX001-049, A multi-center, randomized Phase III study of Rituxamab versus Iodine 1 131 Tositomomab Therapeutic Regimen for patients with relapsed Follicular Non-Hodgkins Lymphoma.